Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
This information helps your provider assess your current metabolic status and anticipate potential side effects
Risk of unsupervised use: Self-adjusting doses without medical guidance or outside a structured wellness plan
Across its client base, Virta has: Discontinued GLP-1 use in over 50% of active users Kept GLP-1 utilization under 25% across all weight loss members Achieved about 5% average weight loss in 90 days, with durable outcomes post-medication Optional outcomes-based contracts available for employers seeking risk alignment Omada Health supports chronic disease and weight management through connected devices, digital coaching, and virtual care teams
Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis
10% Experience Dizziness According to NP2GO, approximately 10% of patients experience dizziness when taking semaglutide, and early reports also note that dizziness was reported in 5% of patients during the first month of treatment, highlighting that early monitoring and simple adjustments often prevent escalation
US$ 23.63
US$ 28.51
US$ 23.45
US$ 24.46
US$ 26.43
US$ 29.91
